Literature DB >> 15099777

Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma.

X Xie1, D Ye, H Chen, W Lu, B Cheng, H Zhong.   

Abstract

OBJECTIVES: To investigate the epithelial ovarian carcinoma (EOC) secretion of interleukin-7 (IL-7).
METHODS: Levels of IL-7 were assayed by enzyme-linked immunoadsorbent assay and IL-7 mRNA, and protein expression in tissues and cell lines were detected by RT-PCR and immunohistochemistry.
RESULTS: The median serum IL-7 level in patients with EOC (32 cases; 32.49 pg/ml) was significantly higher than that of patients with benign tumors (16 cases; 7.59 pg/ml) and healthy women (16 cases; 10.64 pg/ml) (P<0.05). The median peritoneal fluid IL-7 level in patients with EOC (17.39 pg/ml) was slightly higher than that of patients with benign tumors (14.09 pg/ml), but not significantly so (P>0.05). There were positive correlations between the serum and peritoneal fluid IL-7 levels in both ovarian cancer and benign group (P<0.05, both). Only two EOC specimens expressed IL-7 mRNA, and no IL-7 protein positive was found in any specimens.
CONCLUSIONS: Epithelial ovarian carcinoma cells rarely express IL-7, and IL-7 levels are decreased in the ascitic fluid of patients with EOC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099777     DOI: 10.1016/j.ijgo.2003.08.015

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

1.  Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.

Authors:  Chantal Mengus; Clémentine Le Magnen; Emanuele Trella; Kawa Yousef; Lukas Bubendorf; Maurizio Provenzano; Alexander Bachmann; Michael Heberer; Giulio C Spagnoli; Stephen Wyler
Journal:  J Transl Med       Date:  2011-09-26       Impact factor: 5.531

2.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

3.  Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.

Authors:  Raluca Eftimie; Esraa Hassanein
Journal:  J Transl Med       Date:  2018-03-20       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.